Determinantes sociais da saúde de gestantes acompanhadas no prénatal de alto riscoSocial determinants of health of high-risk pregnant women during prenatal follow-up RESUMO Objetivo: avaliar os determinantes sociais da saúde de gestantes acompanhadas no pré-natal de alto risco. Métodos: estudo observacional e transversal, realizado com 276 gestantes de alto risco. A coleta deu-se mediante aplicação de questionário estruturado acerca dos determinantes sociais da saúde, além de dados clínicos e obstétricos das mulheres. Os dados foram analisados através do programa estatístico Jamovi®, versão 0.9, e discutidos segundo o Modelo de Dahlgren e Whitehead. Resultados: as condições individuais; o comportamento e estilo de vida; a rede social e comunitária; e a condição de vida, tais como: trabalho, saúde, educação, saneamento básico e habitação podem constituir fator de risco ou de proteção à saúde da gestante. Conclusão: determinantes como idade, raça, tipo de gestação, nível educacional, a situação de moradia e o acesso aos serviços de saúde foram considerados favoráveis à saúde da maioria das gestantes, porém, a prevalência de gravidez não planejada como comportamento desfavorável. ABSTRACT Objective: to evaluate the social determinants of health of high-risk pregnant women during prenatal follow-up. Methods: observational and cross-sectional study with 276 high-risk pregnant women. Data were collected by applying a structured questionnaire about the social determinants of health, as well as clinical and obstetric data from highrisk pregnant women. Data were analyzed using the Jamovi® statistical software, version 0.9, and discussed according to the Dahlgren and Whitehead's Model. Results: individual conditions; behavior and lifestyle; social and community network; and the condition of life, such as work, health, education, sanitation and housing may constitute a risk or health protection factor for pregnant women. Conclusion: determinants such as age, race, type of pregnancy, educational level, housing situation and access to health services were considered favorable to the health of most pregnant women, but the prevalence of unplanned pregnancy as unfavorable behavior.

Objective: to report the experience of a health team in restructuring service at a mastology outpatient clinic. Methods: an experience report in a public university service mastology outpatient in Ceará between March and April 2020. Service in this outpatient clinic is exclusively for women and who have breast changes for surgical treatments ranging from nodulectomies to mastectomies with oncoplastic. Results: increased COVID-19 cases brought the need to restructure healthcare services. The following steps were followed: identification of scheduled patients, reading of clinical developments in electronic medical records, individual assessment to define whether or not appointment would remain, telephone contact to inform about unscheduling. Among the 555 consultations scheduled for March and April 2020, 316 (56.9%) were maintained. Final considerations: restructuring consultations at a mastology outpatient clinic optimized the waiting time for consultations and avoided crowds at service, providing patient safety.

Objective: to analyze the impacts of the COVID-19 pandemic on breast cancer screening and early diagnosis. Methods: an ecological retrospective study of data from the Department of Informatics of the Unified Health System collected between 2016 and 2020 was carried out. The data collection was guided by a semi-structured script, and the impact of the pandemic on breast cancer screen and diagnosis was established by using a formula and comparing the period of interest to 2020. Results: in Brazil, there was a significant drop in mammograms performed during the COVID-19 pandemic, with a decrease of 361,855 exams from 2016 to 2020. Most diagnostic investigations were conducted with patients between 50 and 59 years, and there was a significant drop in mammograms in women aged under 40 years. Conclusion: the COVID-19 pandemic has negatively impacted screening and early diagnosis of breast cancer due to reduced availability. Contributions to practice: the study reinforces the importance of investing in public policies to face the pandemic scenario so that screening and treatment protocols be well targeted to guarantee better care for cancer patients.

Objective To map the evidence available in the literature on the health-related quality of life of women with breast cancer using hormone therapy. Data sources This review followed the Joanna Briggs Institute methodological recommendations and Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews reporting guidelines. Searches were performed in nine databases using descriptors, synonyms and keywords; grey literature was also included. The review protocol was registered with the Open Science Framework under doi: http://doi.org/10.17605/OSF.IO/347FM . Inclusion criteria were established according to the Population, Concept, and Context strategy. The selection of studies was performed by two independent reviewers with the aid of RAYYAN software and disagreements were resolved by a third reviewer. The main information from the included articles was grouped into textual categories and presented by means of a narrative synthesis. Data Summary A total of 5419 records were identified, of which 42 studies fully met the eligibility criteria. Most were multicenter studies (42.9%) and randomized controlled trials (62%). Most studies addressed anastrozole (39.5%), letrozole (34.2%), and tamoxifen (26.3%), which were studied alone or in combination. The most widely used health-related quality-of-life assessment tool was the EORTC-QLQ-C30. The concomitant use of hormone therapy and cyclin-dependent kinase inhibitors 4 and 6 showed improvement in health-related quality of life. Conclusion In recent years there has been an increase in studies focused on health-related quality of life, and the evidence pointed to relevant information on health-related quality of life and the use of endocrine therapy, tamoxifen in combination with aromatase inhibitors, as well as aromatase inhibitor alone and the use of cyclin-dependent kinase 4 and 6.